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Sickle Cell Data Collection Program:
Three-Year Dissemination and Analysis Plan for Georgia
Over the past several years, Georgia has built a robust set of sickle cell disease (SCD) 
surveillance data for the purpose of developing and disseminating scientific evidence to 
inform policies and practices that will improve the health, quality of life, and life expectancy 
of individuals with SCD. This comprehensive dataset, which will soon include years 2004 
through 2016, is built from newborn screening and vital records; Medicaid, Children’s 
Health Insurance Program, and State Health Benefit Plan administrative claims; hospital and 
emergency department (ED) discharge records; and limited clinical variables from Georgia’s 
three comprehensive SCD centers. This data enables detailed statistics and longitudinal, 
patient-level studies of diagnosis, demographic, geographic, and health care utilization for 
more than 10,000 patients over 13-plus years.
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Sickle cell disease surveillance in Georgia
Three-year plan development
The Georgia Health Policy Center conducted a multistage process to develop a three-
year analysis and dissemination plan to guide use of the SCD surveillance data (Figure 1). 
Priority areas identified by national stakeholders served as a starting point. A Design Team 
representing diverse SCD stakeholder 
groups — affected populations, 
providers, and decision makers/
informers — helped in planning a 
daylong convening. The 49 convening 
participants came from 24 different 
organizations across Georgia and 
beyond. 
The convening produced an extensive 
array of potential study needs and 
dissemination actions. These were 
compiled and distilled with the help of 
the Design Team. 
Priorities were selected as being 
feasible, high-leverage uses of the 
data, and actionable based on needed 
changes identified by the patient and 
provider communities. 
The tables below summarize the three-year plan. The full Sickle Cell Data Collection Program (SCDC) 
report is available at http://ghpc.gsu.edu/download/sickle-cell-data-collection-program-report/.
Dissemination	opportunities	by	target	audience	and	priority	area	
Applications	of	Georgia	SCDC	data	that	are	actionable	and	feasible	in	2017-2020	
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Affected	Populations	
Target	patient	materials	on	use	of	health	systems	in	regions	with	high	utilization		 	 	 	 	 	
Target	patient	and	family	education	in	regions	with	high	mortality	or	complications	 	 	 	 	 	
Target	high-incidence	areas	for	trait	education	and	screening	 	 	 	 	 	
Target	culturally,	linguistically,	and	topically	appropriate	outreach	based	on	demographics	by	region	 	 	 	 	 	
Health	Systems	
Target	outreach	and	case	management	capacity	based	on	service	shortage,	especially	to	ensure	follow-up	 	 	 	 	 	
Allocate	outpatient	resources	and	hours	based	on	prevalent	reasons	for	ED	visits	and	hospitalizations	 	 	 	 	 	
Decide	location	and	hours	of	clinics/telehealth	based	on	accessibility	of	care	across	the	acuity	spectrum	 	 	 	 	 	
Payers	
Decide	quality	measures	to	reflect	evidence-based	practices	 	 	 	 	 	
Target	transition	outreach	on	healthy	behaviors,	insurance	benefits,	and	referrals	based	on	geography	by	age	 	 	 	 	 	
Ensure	provider	contracts	create	care	options	for	all	ages,	needs,	and	acuities	in	reasonable	time	and	distance	 	 	 	 	 	
Policymakers	
Allocate	relevant	social	service	to	areas	with	high	births,	transition-age,	and	aging	populations	 	 	 	 	 	
Decide	provider	workforce	incentives	to	reduce	provider-patient	gaps	by	geography	 	 	 	 	 	
Target	benefits	counseling	and	referrals	by	geography	of	births,	transition-age,	and	aging	populations	 	 	 	 	 	
Providers	
Target	ED,	primary	care,	OB/GYN,	and	hospitalist	education	by	geography	of	patient	population	and	need	 	 	 	 	 	
Decide	referral	strategies	based	on	location	of	specialists	and	SCD	care	providers	 	 	 	 	 	
Adapt	culturally,	linguistically,	and	topically	appropriate	provider	education	based	on	patient	demographics	 	 	 	 	 	
	
Research	
Follow-up	per	findings,	advances,	resources,	and	stakeholder	input	
Actions		
Informed	by	findings	
	
Pediatric	to	adult	transition:	How	complication	and	utilization	patterns	
across	transition	relate	to	insurance	status,	age,	race,	and	geography	
Insurance	and	other	transition-
supportive	policies	
	 	 	 	 	
Pain	treatment	and	opioids:	Prescribing	and	filling	patterns;	treatments	
associated	with	lower	opioid	prescribing;	effect	of	mental	health	services	
Policies	and	practices	for	patients,	
pharmacies,	providers,	EDs	
	 	 	 	 	
Aging:	Complications	and	comorbidities	by	race,	geography,	genotype,	
pregnancy,	menopause	transition,	and	mortality	by	age	group	
Practice	guidance	for	adult	primary	
and	specialty	care	
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